×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

Kristie L. Kahl
A small study showed that, despite national guideline recommendation, conversations between doctors and patients about the benefits and harms of lung cancer screening in those who are at high risk are not happening the way they should be.
Brielle Urciuoli
After success in the non-small cell lung cancer space, immunotherapy is finally making waves in the treatment of small cell lung cancer.
Silas Inman
The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.
Katie Kosko
Researchers may have found a potential new way to treat patients with ovarian or lung cancer who had previously failed other treatments, according to early trial findings published in Annals of Oncology.
 
Brielle Urciuoli
The researchers found that the trial that led to the guidelines – which recommend screening based on age and smoking history – did not include fair representation from all groups across the nation. 
 
Jessica Skarzynski
Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.
Jason M. Broderick
The Food and Drug Administration (FDA) has granted a full approval to frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), based on findings from the phase 3 KEYNOTE-189 trial.
 
Brielle Urciuoli
This is the first approval in the small cell lung cancer space in nearly two decades.
Nancy Bell
Caring for a young person with cancer can be a challenge, explains Nancy Bell.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other